This work is crucial for generalizability. Although it likely that most (but not all) associations will be observed across the world, there will also be population differences, and it is clear that the application of genetic risk scores globally (see below; aim 2) will require risk allele weights derived from the major ancestral populations. Finally, the PGC has engaged academic and industry experts to understand the therapeutic salience of the findings (44). Indeed, the empirical targets of antipsychotic medications are markedly enriched for the results of schizophrenia GWAS and this enrichment became clearer with increasing sample sizes, as has the potential pharmacological relevance of calcium channels for psychiatry (45). The design of rational therapeutics has been an elusive goal for psychiatric indications, and improved genomic knowledge is a pre-competitive activity that can make novel drug discovery more efficient (46).
